Related references
Note: Only part of the references are listed.Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
R. Thiam et al.
ANNALS OF ONCOLOGY (2010)
BRAF, a Target in Melanoma Implications for Solid Tumor Drug Development
Keith T. Flaherty et al.
CANCER (2010)
Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Pazopanib
Petros G. Nikolinakos et al.
CANCER RESEARCH (2010)
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
Bevacizumab: current updates in treatment
Margaret E. M. Van Meter et al.
CURRENT OPINION IN ONCOLOGY (2010)
VEGFR2 is selectively expressed by FOXP3(high) CD4(+) Treg
Hiroyuki Suzuki et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Promoting angiogenesis within the tumor microenvironment: The secret life of murine lymphoid IL-17-producing γδ T cells
Bruno Silva-Santos
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice
Fuminori Abe et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2010)
Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents
Agnieszka Michael et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer
Emer O. Hanrahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Angiogenic Growth Factor and Biomarker Midkine Is a Tumor-Shared Antigen
Jerome Kerzerho et al.
JOURNAL OF IMMUNOLOGY (2010)
IL-17 Contributes to Angiogenesis in Rheumatoid Arthritis
Sarah R. Pickens et al.
JOURNAL OF IMMUNOLOGY (2010)
Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model
Kai-Wen Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT
Laure S. Fournier et al.
RADIOLOGY (2010)
T(H)17 cells in tumour immunity and immunotherapy
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2
Kerrington R. Molhoek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
Junko Ozao-Choy et al.
CANCER RESEARCH (2009)
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
Hong Xin et al.
CANCER RESEARCH (2009)
The COX-2/PGE(2) pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
Alexander Greenhough et al.
CARCINOGENESIS (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
Stephane Oudard et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer
Cecile Badoual et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor
John O. Prior et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Cooperative Induction of Hypoxia-Inducible Factor-1α and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis
Muhammad Zaeem Noman et al.
JOURNAL OF IMMUNOLOGY (2009)
Angiostatin anti-angiogenesis requires IL-12: The innate immune system as a key target
Adriana Albini et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
Roland Houben et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Angiostatic activity of the antitumor cytokine interleukin-21
Karolien Castermans et al.
BLOOD (2008)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Clinical biomarkers of angiogenesis inhibition
Aaron P. Brown et al.
CANCER AND METASTASIS REVIEWS (2008)
HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
Rose Du et al.
CANCER CELL (2008)
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
The soluble α chain of interleukin-15 receptor:: A proinflammatory molecule associated with tumor progression in head and neck cancer
Cecile Badoual et al.
CANCER RESEARCH (2008)
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients:: CD1c+ dendritic cell frequency predicts progression-free survival
Hester van Cruijsen et al.
CLINICAL CANCER RESEARCH (2008)
Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia
Michail V. Sitkovsky et al.
CLINICAL CANCER RESEARCH (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
STAT3 as a target for cancer drug discovery
Luca Costantino et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Role of Stat3 in suppressing anti-tumor immunity
Marcin Kortylewski et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1α
Jeremy Ben-Shoshan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Tuning microenvironments: Induction of regulatory T cells by dendritic cells
Yasmine Belkaid et al.
IMMUNITY (2008)
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells
Ilaria Marigo et al.
IMMUNOLOGICAL REVIEWS (2008)
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice
Maciej Kujawski et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
Silvia Dellapasqua et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients
Nadege Bercovici et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
W. Zhao et al.
LEUKEMIA (2008)
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Juliana Hamzah et al.
NATURE (2008)
Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma
Brian I. Rini et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment
Frederic Dayan et al.
CANCER MICROENVIRONMENT (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
Ping-Ying Pan et al.
BLOOD (2008)
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Farbod Shojaei et al.
NATURE (2007)
Targeting NOX, INOS and COX-2 in inflammatory cells: Chemoprevention using food phytochemicals
Akira Murakami et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis
Yusuke N. Kimura et al.
CANCER SCIENCE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Olivier Rixe et al.
LANCET ONCOLOGY (2007)
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
Richard W. Griffiths et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
John M. L. Ebos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma
Christoph Bergmann et al.
CANCER RESEARCH (2007)
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses
Ingo Fricke et al.
CLINICAL CANCER RESEARCH (2007)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Farbod Shojaei et al.
NATURE BIOTECHNOLOGY (2007)
Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells
F. Farace et al.
ANNALS OF ONCOLOGY (2007)
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
Elizabeth A. Manning et al.
CLINICAL CANCER RESEARCH (2007)
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor based antitumor vaccine
Paola Filipazzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor
Anat Norden-Zfoni et al.
CLINICAL CANCER RESEARCH (2007)
The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2α but not HIF-1α
Stephen B. Fox et al.
PROSTATE (2007)
Tregs and rethinking cancer immunotherapy
Tyler J. Curiel
JOURNAL OF CLINICAL INVESTIGATION (2007)
Costimulation, coinhibition and cancer
Brant A. Inman et al.
CURRENT CANCER DRUG TARGETS (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Treatment options in renal cell carcinoma: past, present and future
S. Oudard et al.
ANNALS OF ONCOLOGY (2007)
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF - Secreting cancer immunotherapy
Betty Li et al.
CLINICAL CANCER RESEARCH (2006)
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib:: Pilot study using dynamic contrast-enhanced Doppler ultrasound
Michele Lamuraglia et al.
EUROPEAN JOURNAL OF CANCER (2006)
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
Dong Wook Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes
Manish Aghi et al.
CANCER RESEARCH (2006)
Antiangiogenic and antitumor activities of IL-27
Motomu Shimizu et al.
JOURNAL OF IMMUNOLOGY (2006)
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors
Anita E. M. Dirkx et al.
FASEB JOURNAL (2006)
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers
C Badoual et al.
CLINICAL CANCER RESEARCH (2006)
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
B Huang et al.
CANCER RESEARCH (2006)
VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells
M Grunewald et al.
CELL (2006)
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine
AR Haas et al.
CLINICAL CANCER RESEARCH (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pro-angiogenic cytokines and their role in tumor angiogenesis
Gera Neufeld et al.
CANCER AND METASTASIS REVIEWS (2006)
Role of tumor-associated macrophages in tumor progression and invasion
Alberto Mantovani et al.
CANCER AND METASTASIS REVIEWS (2006)
Paradoxical roles of the immune system during cancer development
KE de Visser et al.
NATURE REVIEWS CANCER (2006)
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
M Kortylewski et al.
NATURE MEDICINE (2005)
Tumor inflammatory angiogenesis and its chemoprevention
A Albini et al.
CANCER RESEARCH (2005)
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis
M Numasaki et al.
JOURNAL OF IMMUNOLOGY (2005)
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
PC Rodriguez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways
S Laxmanan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells
F Baratelli et al.
JOURNAL OF IMMUNOLOGY (2005)
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer
S Sharma et al.
CANCER RESEARCH (2005)
Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation
MM Dikov et al.
JOURNAL OF IMMUNOLOGY (2005)
Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis
TX Xie et al.
ONCOGENE (2004)
Multiple roles of COX-2 in tumor angiogenesis: A target for antiangiogenic therapy
S Gately et al.
SEMINARS IN ONCOLOGY (2004)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma
Y Akasaki et al.
JOURNAL OF IMMUNOLOGY (2004)
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells
P Serafini et al.
CANCER RESEARCH (2004)
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis
E Giraudo et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome)
A Ciré et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate
N Boissel et al.
LEUKEMIA (2004)
IL-12 regulates an endothelial cell-lymphocyte network: Effect on metalloproteinase-9 production
S Mitola et al.
JOURNAL OF IMMUNOLOGY (2003)
Synergy between tumor immunotherapy and antiangiogenic therapy
S Nair et al.
BLOOD (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Interleukin-17 promotes angiogenesis and tumor growth
M Numasaki et al.
BLOOD (2003)
Cyclooxygenase-2-issued prostaglandin E-2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions
H Harizi et al.
JOURNAL OF IMMUNOLOGY (2002)
TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells
YM Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer
E Tartour et al.
LANCET (2001)
Stem cell factor and FLT3-ligand are strictly required to sustain the long-term expansion of primitive CD34+DR- dendritic cell precursors
A Curti et al.
JOURNAL OF IMMUNOLOGY (2001)
VEGF as a Mediator of tumor-associated immunodeficiency
JE Ohm et al.
IMMUNOLOGIC RESEARCH (2001)
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
N Haicheur et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Share Paper
